| Trial ID: | L0448 |
| Source ID: | NCT04187339
|
| Associated Drug: |
NGM395
|
| Title: |
A Phase 1, Randomized, Placebo-controlled, Double-blind, Two-part Study to Evaluate the Safety and Tolerability of NGM395 in Adult Obese Patients (Part 1) and in Adult Patients With Nonalcoholic Fatty Liver Disease (NAFLD) (Part 2).
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Obesity;NAFLD
|
| Interventions: |
Biological: NGM395;Biological: NGM395;Biological: NGM395;Biological: NGM395;Biological: NGM395;Biological: NGM395;Other: Placebo
|
| Outcome Measures: |
Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)Serum Concentration of NGM395
|
| Sponsor/Collaborators: |
NGM Biopharmaceuticals, Inc
|
| Gender: |
All
|
| Age: |
18 Years65 Years
|
| Phases: |
Phase 1
|
| Enrollment: |
38
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
| Start Date: |
03/12/2019
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
2 August 2021
|
| Locations: |
Australia
|
| URL: |
https://clinicaltrials.gov/show/NCT04187339
|
